# The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions

> **NCT03216278** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 284 (actual)

## Conditions studied

- Healthy Subjects in Fasted and Fed State

## Interventions

- **DRUG:** Dapagliflozin/metformin XR 5/500mg
- **DRUG:** Dapagliflozin/metformin XR 5/500 mg
- **DRUG:** Dapagliflozin/metformin XR 5/500mg
- **DRUG:** Dapagliflozin/metformin XR 5/500mg
- **DRUG:** Dapagliflozin/metformin XR 10/1000mg
- **DRUG:** Dapagliflozin/metformin XR 10/1000mg
- **DRUG:** Dapagliflozin/metformin XR 10/1000mg
- **DRUG:** Dapagliflozin/metformin XR 10/1000mg

## Key facts

- **NCT ID:** NCT03216278
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-26
- **Primary completion:** 2018-05-22
- **Final completion:** 2018-05-22
- **Target enrollment:** 284 (ACTUAL)
- **Last updated:** 2018-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03216278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03216278, "The Purpose of the Study is to Compare Two Fixed Dose Combination Tablets of Dapagliflozin/Metformin XR in Healthy Subjects Under Fasting and Fed Conditions". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03216278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*